Literature DB >> 34344472

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma.

Olivia Lauk1, Miriam Patella1, Thomas Neuer1, Bianca Battilana1, Thomas Frauenfelder2, Thi Dan Linh Nguyen-Kim2, Walter Weder1, Claudio Caviezel1, Sven Hillinger1, Ilhan Inci1, Isabelle Opitz3.   

Abstract

OBJECTIVES: Tumor thickness and tumor volume measured by computed tomography (CT) were suggested as valuable prognosticator for patients' survival diagnosed with malignant pleural mesothelioma (MPM). The purpose was to assess the accuracy of CT scan based preoperatively measured tumor volume and thickness compared to actual tumor weight of resected MPM specimen and pathologically assessed tumor thickness, as well as an analysis of their impact on overall survival (OS).
METHODS: Between 09/2013-08/2018, 74 patients were treated with induction chemotherapy followed by (extended) pleurectomy/decortication ((E)PD). In 53 patients, correlations were made between CT-measured volume and -tumor thickness (cTV and cTT) and actual tumor weight (pTW) based on the available values. Further cTV and pT/IMIG stage were correlated using Pearson correlation. Overall survival (OS) was calculated with Kaplan Meier analysis and tested with log rank test. For correlation with OS Kaplan-Meier curves were made and log rank test was performed for all measurements dichotomized at the median.
RESULTS: Median pathological tumor volume (pTV) and pTW were 530 ml [130 ml - 1000 ml] and 485 mg [95 g - 982 g] respectively. Median (IQR) cTV was 77.2 ml (35.0-238.0), median cTT was 9.0 mm (6.2-13.7). Significant association was found between cTV and pTV (R = 0.47, p < 0.001) and between cTT and IMIG stage (p = 0,001) at univariate analysis. Multivariate regression analysis revealed, that only cTV correlates with pTV. Median follow-up time was 36.3 months with 30 patients dead at the time of the analysis. Median OS was 23.7 months. 1-year and 3-year survival were 90 and 26% respectively and only the cTV remained statistically associated with OS.
CONCLUSION: Preoperatively assessed CT tumor volume and actual tumor volume showed a significant correlation. CT tumor volume may predict pathological tumor volume as a reflection of tumor burden, which supports the integration of CT tumor volume into future staging systems.
© 2021. The Author(s).

Entities:  

Keywords:  Computed tomography tumor volume; Macroscopic complete resection; Malignant pleural mesothelioma; Pathological tumor weight; Pleurectomy/decortication

Year:  2021        PMID: 34344472     DOI: 10.1186/s40644-021-00415-5

Source DB:  PubMed          Journal:  Cancer Imaging        ISSN: 1470-7330            Impact factor:   3.909


  21 in total

1.  Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?

Authors:  T Frauenfelder; M Tutic; W Weder; R P Götti; R A Stahel; B Seifert; I Opitz
Journal:  Eur Respir J       Date:  2011-01-27       Impact factor: 16.671

2.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P Baas; D Fennell; K M Kerr; P E Van Schil; R L Haas; S Peters
Journal:  Ann Oncol       Date:  2015-07-28       Impact factor: 32.976

Review 3.  Volumetric assessment in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

4.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Eur Respir J       Date:  2009-08-28       Impact factor: 16.671

Review 5.  The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.

Authors:  Harvey Pass; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck; Anna Nowak; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2016-09-23       Impact factor: 15.609

6.  The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Authors:  Anna K Nowak; Kari Chansky; David C Rice; Harvey I Pass; Hedy L Kindler; Lynn Shemanski; Andrea Billé; Robert C Rintoul; Hasan F Batirel; Charles F Thomas; Joseph Friedberg; Susana Cedres; Marc de Perrot; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2016-09-26       Impact factor: 15.609

7.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

8.  Malignant pleural mesothelioma: an epidemiological perspective.

Authors:  Benjamin M Robinson
Journal:  Ann Cardiothorac Surg       Date:  2012-11

9.  British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Authors:  Ian Woolhouse; Lesley Bishop; Liz Darlison; Duneesha De Fonseka; Anthony Edey; John Edwards; Corinne Faivre-Finn; Dean A Fennell; Steve Holmes; Keith M Kerr; Apostolos Nakas; Tim Peel; Najib M Rahman; Mark Slade; Jeremy Steele; Selina Tsim; Nick A Maskell
Journal:  Thorax       Date:  2018-03       Impact factor: 9.139

10.  Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.

Authors:  Ritu R Gill; Beow Y Yeap; Raphael Bueno; William G Richards
Journal:  J Natl Cancer Inst       Date:  2018-03-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.